TELA logo

TELA Bio, Inc. Stock Price

NasdaqGM:TELA Community·US$61.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

TELA Share Price Performance

US$1.56
-1.06 (-40.46%)
US$1.56
-1.06 (-40.46%)
Price US$1.56

TELA Community Narratives

There are no narratives available yet.

Recent TELA News & Updates

Further Upside For TELA Bio, Inc. (NASDAQ:TELA) Shares Could Introduce Price Risks After 32% Bounce

Jul 18
Further Upside For TELA Bio, Inc. (NASDAQ:TELA) Shares Could Introduce Price Risks After 32% Bounce

Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

May 21
Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Mar 31
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Nov 09
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

TELA Bio, Inc. Key Details

US$75.3m

Revenue

US$24.2m

Cost of Revenue

US$51.1m

Gross Profit

US$91.8m

Other Expenses

-US$40.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.03
Gross Margin
67.81%
Net Profit Margin
-54.12%
Debt/Equity Ratio
450.6%

TELA Bio, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Reasonable growth potential and fair value.

3 Risks
2 Rewards

About TELA

Founded
2012
Employees
209
CEO
Antony Koblish
WebsiteView website
www.telabio.com

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. In the last year, the market has climbed 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›